Tribute Pharmaceuticals Canada Inc. (fka TBUFF)

[Ruffieruff]

Part 2

Re: URACRYST SALES PROJECTION 7-May-10 12:42 pm
PART 2-There is not a stock out here in this niche that has the same profile that Stellar has and it is one of the most undervalued plays in my port...which is why i keep adding...some today even. If you don't own it I would at least do the R&D as I think that among all the stocks in my ports this is the best portfolio maker of all. This one year chart says it better than I ever could--then a para from the WPI write up by Cohen---->only 23m shares out---another big plus---->

http://bigcharts.marketwatch.com/quickch...

=============================================
FROM COHEN AND CO WPI RECCOMENDATION-

Uracyst Could Have Peak Sales Of $200MM
In recent years, scientists have started to use the terms bladder pain syndrome
(BPS) or painful bladder syndrome (PBS) to describe cases with painful urinary
symptoms that may not meet the strictest definition of IC. Medical literature
estimates that about 1-2MM Americans have IC/PBS and a majority of these
patients are women. Assuming U.S. patient population of about 2MM, about 50%
diagnosed and treated, peak penetration within that treated population of 35%,
seven-to-ten vials per patient annually, and $75 wholesale price per vial, Uracyst
could be approximately $200MM in peak potential. These estimates are in line
with Elmiron?s current annual sales, which as noted earlier were roughly
$170MM and on approximately 500,000 prescriptions in 2009.